Literature DB >> 2877701

Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.

H De Cuyper, J Bollen, H M van Praag, D Verstraeten.   

Abstract

For this open study, we selected 21 chronic psychotic female in-patients (16 of them schizophrenics) who were being maintained on oral neuroleptics. After a wash-out period, they were treated by intramuscular depot injections of haloperidol decanoate, once a month for four months. The dose was calculated from the previous oral dosage, and the amount of the first injection was double that of the three following injections. Relatively stable plasma levels of haloperidol were achieved with the first injection, and corresponded to those observed with oral medication. A very significant correlation was found between plasma level and the dose administered, but not between plasma level and therapeutic effect. The clinical condition of about two-thirds of the patients remained unchanged or improved, compared with the period of oral treatment. During the first two months of treatment, there was more rigidity and tremor, but from the third month, the extrapyramidal symptoms were less pronounced than during the period of oral neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877701     DOI: 10.1192/bjp.148.5.560

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  7 in total

Review 1.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Role of D-1 and D-2 receptor stimulation in sensitization to amphetamine-induced circling behavior and in expression and extinction of the Pavlovian conditioned response.

Authors:  K L Drew; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.

Authors:  D H Wiles; R G McCreadie; A Whitehead
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.

Authors:  R Beresford; A Ward
Journal:  Drugs       Date:  1987-01       Impact factor: 9.546

Review 5.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

6.  Comparative bioavailability study of two haloperidol decanoate containing products.

Authors:  G van Weringh; B J Komen; R E Thieme; R T van der Hoeven; T Vos
Journal:  Pharm World Sci       Date:  1994-12-02

7.  Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting.

Authors:  Rosaria Di Lorenzo; Paola Ferri; Michela Cameli; Sergio Rovesti; Chiara Piemonte
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-07       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.